Athira Pharma, Inc will initiate an open-label extension study for two ongoing clinical trials investigating ATH-1017 to treat Alzheimer’s disease. Both clinical trials — the Phase 2/3 LIFT-AD (NCT04488419) and Phase 2 ACT-AD (NCT04491006) — are investigating ATH-1017, a small molecule designed to enhance the effect of hepatocyte growth…
People affected by Alzheimer’s disease and related dementias are invited to register for the Mayo Clinic Conference on Brain Health and Dementia, which also pays tribute to all that the community has been going through during the COVID-19 pandemic. Held virtually on Oct. 29 from 9:15am to 2:15pm…
Researcher Amir Hirsa has found a way 240 miles above the Earth’s surface to study the aggregation of proteins that are the hallmarks of Alzheimer’s and Parkinson’s diseases, and type 2 diabetes. Hirsa, PhD, is a professor of mechanical and aerospace engineering with a joint appointment in chemical and biological engineering…
A new documentary released in advance of World Alzheimer’s Day today tells the story of a Worcester, Massachusetts, photographer and art professor who captured the gradual cognitive decline of his late father through a large format black-and-white camera. “With Dad,” which is available to stream on the…
Amyloid-beta produced in peripheral organs, specifically the liver, may be implicated in the brain neurodegeneration observed in Alzheimer’s disease, according to a mouse study. The study, “Synthesis of human amyloid restricted to liver results in an Alzheimer disease–like neurodegenerative phenotype,” was published in PLOS Biology. Deposits of amyloid-beta…
Research institutions in North Carolina and Texas have become the newest members of a national network of Alzheimer’s Disease Research Centers (ADRCs), which are at the forefront of research into Alzheimer’s and related dementias. The ADRCs, a project funded by the National Institute on Aging (NIA), have…
Six months of daily supplements of omega-3 increased the levels of two biomarkers of inflammation and nerve damage in the cerebrospinal fluid (CSF) of people with Alzheimer’s disease, according to a post-hoc analysis of data from the OmegAD clinical trial. While these preliminary findings suggest that omega-3 supplements may…
AlzeCure Pharma has been granted approval by Swedish regulatory authorities to start its third Phase 1 study of ACD856, the company’s leading therapeutic candidate for Alzheimer’s disease. The study is designed to test multiple ascending doses of the medication, which means that the amount of ACD856 will be…
Federal lawmakers are asking the U.S. Food and Drug Administration (FDA) to provide additional data and documents related to the agency’s controversial decision to grant accelerated approval to Biogen‘s Aduhelm (aducanumab) as a treatment for Alzheimer’s disease. U.S. Rep. Frank Pallone, Jr., chair of the House Committee on…
The Adira Foundation is inviting people with neurodegenerative diseases and their caregivers to join a grant proposal review committee. A nonprofit foundation, its mission is to unite people affected by some of most common neurodegenerative diseases — namely, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and multiple sclerosis —…
Get regular updates to your inbox.